日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial

在转移性去势抵抗性前列腺癌患者接受多西他赛和阿比特龙治疗后出现疾病进展的情况下,新型雄激素受体抑制剂氘代沙鲁胺的疗效:来自随机 III 期 HC-1119-04 试验的结果

Wu, Junlong; Li, Xinghai; Gu, Chengyuan; Hua, Lixin; Liu, Ranlu; Li, Jun; Qiu, Mingxing; Guo, Jianming; Dong, Haiying; Ji, Zhigang; Xie, Liping; Zhu, Shaoxing; Zhang, Xuhui; Chen, Peng; Jiang, Shusuan; Sun, Zhongquan; Xu, Danfeng; Chen, Hui; Shi, Benkang; Wang, Yujie; Pu, Jinxian; Perabo, Frank; Chen, Yuanwei; Ye, Dingwei

Noninvasive Early Detection and Recurrence Monitoring for Non-Muscle-Invasive Bladder Cancer via Urine Tumor DNA: A Prospective Clinical Study

通过尿液肿瘤DNA进行非肌层浸润性膀胱癌的无创早期检测和复发监测:一项前瞻性临床研究

Wu, Junlong; Jin, Shengming; Bai, Qianming; Wang, Huina; Cheng, Huanqing; Zhou, Xiaoyan; Shen, Yijun; Ma, Chunguang; Gu, Chengyuan; Chen, Hui; Zhang, Yafeng; Chen, Libin; Shariat, Shahrokh F; Lou, Feng; Cao, Shanbo; Zhu, Yiping; Ye, Dingwei

First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC

T3011(一种表达IL-12和PD-1的溶瘤性HSV抗体)的首次人体I/IIa期研究,通过瘤内注射(IT)给药,作为单药疗法治疗晚期实体瘤,包括复发性或转移性头颈部鳞状细胞癌(HNSCC)。

Ji, Dongmei; Fu, Wenmin; Liu, Yonghong; Shen, Weina; Kuang, Muyu; Ning, Zhouyu; Sang, Youzhou; Chen, Guangliang; Zhang, Jian; Zhou, Zijie; Xu, Dashuang; Jin, Xu; Wu, Junlong; Zhou, Xusha; Zhao, Jing; Wang, Lei; Liu, Yukun; Zhang, Xi; Yan, Runbin; Chen, Xiaoqing; Zhou, Grace; Niu, Jiaxin; Hu, Xichun

Mitogen-activated protein kinase kinase 4 (MKK4) as a promising therapeutic target in liver diseases: a review

丝裂原活化蛋白激酶激酶4 (MKK4) 作为肝脏疾病中一个有前景的治疗靶点:综述

Liu, Pan; Liu, Yangyang; Cheng, Li; Bao, Tingting; Li, Jingjing; Wu, Junlong; Han, Jicheng; Li, Ting; Zhang, Dongna

Efficacy, Safety, and Tolerability of Subcutaneous Efgartigimod PH20 in Chinese Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Prespecified Subpopulation Analysis of the Multicentre, Randomised-Withdrawal, Double-Blind, Placebo-Controlled, Phase II ADHERE Trial

皮下注射 Efgartigimod PH20 治疗中国慢性炎症性脱髓鞘性多发性神经病患者的疗效、安全性和耐受性:一项多中心、随机撤药、双盲、安慰剂对照的 II 期 ADHERE 试验的预设亚组分析

Lin, Jie; Ding, Man; Wang, Qinzhou; Chang, Ting; Zhao, Yuanqi; Da, Yuwei; Tan, Song; Hong, Daojun; Jiang, Haishan; Zou, Zhangyu; Yang, Huan; Bu, Bitao; Liang, Hui; Wang, Yiqi; Guo, Aihong; He, Dian; Wang, Yuzhong; Ding, Jing; Guo, Junhong; Shi, Jianquan; Zhang, Yali; Liu, Jing; Liu, Jia; Chen, Lijuan; Wu, Junlong; Shao, Jing; Hofman, Erik; Hoorick, Benjamin Van; Mole, Trevor; Li, Wei; Lu, Zuneng

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study

新辅助氟哌啶醇联合阿比特龙治疗局限性高危前列腺癌(FAST-PC):一项单臂 II 期研究

Zhang, Tingwei; Wang, Beihe; Wei, Yu; Gan, Hualei; Fang, Bangwei; Li, Xiaomeng; Wu, Junlong; Bian, Xiaojie; Wang, Jianfei; Freedland, Stephen J; Huang, Shenglin; Ye, Dingwei; Zhu, Yao

Genomic Landscape and Clinical Relevance in Chinese Patients With Upper Tract Urothelial Carcinoma

中国上尿路尿路上皮癌患者的基因组图谱及其临床意义

Shang, Zhi; Pan, Jian; Wang, Shanshan; Gu, Chengyuan; Zhang, Hailiang; Shi, Guohai; Cao, Dalong; Zhu, Yu; Zhu, Yao; Shen, Yijun; Zhu, Yiping; Jin, Shengming; Wu, Junlong; Ye, Dingwei

Comprehensive analysis of the LINC01122/TPD52 axis as a predictive biomarker in prostate adenocarcinoma

对LINC01122/TPD52轴作为前列腺腺癌预测性生物标志物的综合分析

Shang, Zhi; Jin, Shengming; He, Yandong; Zhu, Yiping; Zhang, Hailiang; Wu, Junlong; Hong, Zhe; Ye, Dingwei

[Corrigendum] miR‑504 promotes tumour growth and metastasis in human osteosarcoma by targeting TP53INP1

[更正] miR-504 通过靶向 TP53INP1 促进人类骨肉瘤的肿瘤生长和转移

Cai, Qingchun; Zeng, Sixiang; Dai, Xing; Wu, Junlong; Ma, Wei

Exploratory analysis of the molecular and genomic landscape of upper tract urothelial carcinoma using long-read sequencing

利用长读长测序技术对上尿路尿路上皮癌的分子和基因组图谱进行探索性分析

Shang, Zhi; Ling, Xiuxin; Jin, Shengming; Cao, Zhenhua; Wu, Junlong; Ye, Dingwei